大剂量皮质激素治疗口咽癌幸存者迟发性下组颅神经病变:I期剂量探索试验中期分析
STOP LCNP I/II期剂量探索试验及平行登记研究前瞻性评估大剂量皮质激素治疗放疗相关下组颅神经病变(LCNP)的安全性、可行性与症状反应。3 mg/kg泼尼松组5例中3例在减量后1-2周达临床意义改善,但6-10周未维持,客观功能与电生理指标无一致改善。
要点
- 口服泼尼松3 mg/kg×5天(2周减量)在口咽癌幸存者LCNP中可行且耐受,失眠为最常见不良事件。
- 3 mg/kg组5例中3例达MDASI-HN Top 5临床意义改善,但6-10周未维持。
- 两种剂量均未在临床医生评定的延髓功能或电生理指标上观察到一致改善。
核心结论
- 大剂量皮质激素治疗在长期头颈癌幸存者LCNP中可行且耐受,3 mg/kg组多数获短期症状改善但不持久,且未反映于临床医生评定指标。
研究设计与样本
- STOP LCNP I/II期剂量探索试验(NCT04151082)及平行登记研究的中期I期报告。
- 入组为放疗后≥2年、肌电图确认LCNP(CN XII±X)、无结构/恶性病因的无病口咽癌幸存者。
- I期测试口服泼尼松1 mg/kg(剂量1,n=3)或3 mg/kg(剂量2,n=5)每日5天(2周减量)。
- 平行登记研究(n=6)纳入更广泛头颈癌幸存者接受1 mg/kg治疗。
- 预设规则性剂量递增决策基于耐受性与症状反应(主要终点)。
主要发现
- 所有方案可行且耐受良好,失眠(n=5,1级)为最常见不良事件,无治疗中止。
- 减量后1-2周MDASI-HN Top 5中位变化:1 mg/kg组-0.2,3 mg/kg组-1.6。
- 3 mg/kg组5例中3例达临床意义改善,但6-10周未维持。
- 两种剂量水平均未在客观功能或电生理指标上观察到一致改善。
关键数值与推荐
- 主要终点症状反应定义为MDASI-HN Top 5平均症状评分自基线至减量后1-2周下降≥1.315单位。
- 剂量1为口服泼尼松1 mg/kg每日5天(2周减量),剂量2为3 mg/kg每日5天(2周减量)。
临床怎么用
- 对放疗后≥2年、肌电图确认LCNP且无结构/恶性病因的口咽癌幸存者,可考虑大剂量皮质激素但需告知短期改善可能不持久。
- 3 mg/kg方案短期症状改善比例较高,但缺乏客观功能与电生理改善证据,决策需结合个体情况。
局限性
- 本文为I期剂量探索中期分析,样本量小(I期n=8,登记n=6),结果需进一步验证。
- 短期症状改善在6-10周未维持,且未反映于临床医生评定指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation-associated lower cranial neuropathy (LCNP) is a debilitating late complication among head and neck cancer (HNC) survivors, leading to progressive dysphagia, aspiration, and loss of nutritional independence. No proven therapies exist for LCNP. This phase I/II dose-finding trial (STOP LCNP, NCT04151082) and parallel registry study prospectively evaluated the safety, feasibility, tolerability, and symptomatic response of high-dose corticosteroid therapy for radiation-associated LCNP. METHODS AND MATERIALS: Interim phase I dose-finding report from the STOP LCNP trial. Eligible participants were disease-free oropharyngeal cancer survivors ≥2 years after radiation therapy with electromyography-confirmed LCNP (CN XII ± X) absent structural/malignant etiology. Phase I testing included oral prednisone 1 mg/kg (dose 1, n = 3) or 3 mg/kg (dose 2, n = 5) daily for 5 days (2-week taper). A parallel registry (n = 6) enrolled broader HNC survivors treated with 1 mg/kg. Rule-based phase I dose-escalation decisions were prespecified for tolerability and symptom response (primary endpoint); ≥1.315-unit decrease in MD Anderson Symptom Inventory-Head and Neck Module Top 5 mean symptom score from baseline to 1 to 2 weeks posttaper indicated clinically meaningful improvement. Secondary endpoints included clinician-graded measures of bulbar function, electromyography, and patient-reported outcome measures. RESULTS: All regimens were feasible and well tolerated. Insomnia (n = 5, grade 1) was the most frequent adverse event with no treatment discontinuations. At 1 to 2 weeks posttaper, the median MD Anderson Symptom Inventory-Head and Neck Module Top 5 change was -0.2 in 1 mg/kg and -1.6 in 3 mg/kg; 3 of 5 patients receiving 3 mg/kg achieved clinically meaningful improvement not maintained at 6 to 10 weeks. No consistent improvements were observed in objective functional or electrophysiologic measures at either dose level. CONCLUSIONS: High-dose corticosteroid therapy was feasible and tolerable in long-term HNC survivors with LCNP. Short-term symptomatic improvement was achieved in the majority treated with 3 mg/kg but was not reflected in clinician-graded measures of bulbar function and not durable by 6 to 10 weeks at either dosing.
引用
- Belal ZAS, Peterson CB, Barbon CE, et al. STOP Lower Cranial Neuropathy: High-Dose Corticosteroid Therapy for Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors: Interim Analysis of a Phase I Dose-Finding Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42782239. doi:10.1016/j.ijrobp.2026.08.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。